Cardiovascular disease (CVD) is the world’s leading cause of morbidity and mortality as well as the health industry’s most costly disease for treatment. Yet, despite recent advances in its treatment, more effective and accessible ways to tackle CVDs remain to be discovered. Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE) is taking on the challenge to develop new ways to treat CVD with innovative technologies allowing early prediction and intervention, so people can stay a step ahead of the disease. These technologies can also reduce the human cost, as well as alleviate both the financial and social burden, on the healthcare system.

​

In collaboration with the University of Oxford and the Karolinska Institutet, Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) was established under City University of Hong Kong in 2020. The COCHE, supported financially by Innovation and Technology Commission (ITC), was admitted to Inno-Health cluster of InnoHK Programme which is a major R&D initiative of the Hong Kong Special Administrative Region Government. We are developing flexible sensing, biomedical and molecular imaging, nano-biosensing, and AI in health with the focus on innovative wearables that collect key vital signs, including but not limited to continuous blood pressure and electrocardiogram signals on an unobtrusive and real-time basis. The collected data is transmitted for further analysis and integration with other biomarkers, paving the way for the early detection and diagnosis of possible acute cerebro-cardiovascular diseases.